Flightpath's R&D team is building an array of technologies against nature’s most biologically sophisticated pathogens.


Therapeutic Development Programs

Clinical Development Stage.
Product Name Program Primary Pathogen Discovery Preclinical IND Phase
I
Phase
II
Phase
III
Marketed Development Partner
FP-100 Lyme disease B. burgdorferi The Steven & Alexandra Cohen Foundation

Description:

FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple gram-negative bacteria

Ownership:

Global development and commercialization rights owned by Flightpath Biosciences

FP-100 Cancer (CRC, OSCC) Fusobacterium Nucleatum internal

Description:

FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple gram-negative bacteria

Ownership:

Global development and commercialization rights owned by Flightpath Biosciences

FP-200 Oral Health (Periodontal Disease) Fusobacterium,
T. denticola
ADA Forsyth Institute

Description:

FP-200 is a new, narrow-spectrum antibiotic with activity against multiple gram-negative bacteria responsible for local oral disease and systemic chronic illnesses.

Development Partnership:

Co-development agreement between the ADA Forsyth Institute and Flightpath Biosciences.

Goal: to determine the impact of eliminating gram-negative bacteria but not commensal bacteria from the oral cavity. The team will also evaluate implications on downstream systemic chronic diseases (e.g. neurodegenerative disease)

FP-100 Syphilis & NTD yaws T. pallidum,
T. pallidum pertinue
internal

Description:

FP-100 is a novel, orally available narrow-spectrum antibiotic with activity against multiple spirochetal and gram-negative bacteria

Ownership:

Global development and commercialization rights owned by Flightpath Biosciences

FP-300 Women's Health (Endometriosis, Infertility, Pre-term Birth) Fusobacterium internal

Description:

FP-300 is a narrow-spectrum antibiotic with activity against Fusobacterium Nucleatum

Ownership:

Global development and commercialization rights owned by Flightpath Biosciences

Flightpath is seeking partners to develop agricultural and animal health applications.

Contact Us for more information